Drugs.com - Clinical Trials

Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron

NEW YORK--(BUSINESS WIRE) April 14, 2025 -- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for...

Apr 14, 2025 - 21:02
 0
Pfizer Discontinues Development of Oral GLP-1 Receptor Agonist Danuglipron
NEW YORK--(BUSINESS WIRE) April 14, 2025 -- Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral glucagon-like peptide-1 (GLP-1) receptor agonist, which was being investigated for...
Read More

Tags:

Previous Article

Amgen bumps up pay for longtime CEO Robert Bradway 8% to $24.4M

Next Article

Dutch F-35 Executes First Live Classified Data Share Outside the U.S.

Related Posts

Novo Nordisk Introduces NovoCare® Pharmacy, Lowering Cost of All Doses of FDA-Approved Wegovy® (semaglutide) to $499 per Month

Novo Nordisk Introduces NovoCare® Pharmacy, Lowering Co...

Mar 11, 2025  0

Axsome Therapeutics Announces Successful Completion and Results of Phase 3 Clinical Program of AXS-05 in Alzheimer’s Disease Agitation

Axsome Therapeutics Announces Successful Completion and...

Feb 9, 2025  0

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces FDA Fast Track and Enrollment U...

Feb 27, 2025  0